Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8309124 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(1 year, 27 days from now) | |
US8394407 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(1 year, 27 days from now) | |
US9040085 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(1 year, 27 days from now) | |
US9186332 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(1 year, 27 days from now) | |
US9504699 | HORIZON | Delayed-release glucocorticoid treatment of rheumatoid disease |
Aug, 2027
(4 years from now) | |
US8168218 | HORIZON | Delayed release tablet with defined core geometry |
Jan, 2028
(4 years from now) |
Market Authorisation Date: 26 July, 2012
Treatment: Treatment of diseases or conditions by the use of a delayed release 1, 2, or 5 mg prednisone tablet; Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet; ...
Dosage: TABLET, DELAYED RELEASE;ORAL
14
United States
3
Slovenia
3
China
3
European Union
2
Israel
2
South Africa
2
Denmark
2
Mexico
2
Australia
2
Singapore
2
Brazil
2
Portugal
2
Cyprus
2
Spain
2
Korea, Republic of
2
Poland
2
Japan
2
Canada
1
IB
1
Austria
1
Hong Kong
1
Russia
1
Morocco
1
Norway
1
Croatia
1
Malaysia
1
RS
1
United Kingdom
1
Ukraine
1
EA
1
Tunisia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic